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This project investigated the relationship between bipolar disorder and 
menopause in 41 research participants at the University of Massachusetts 
Medical School, as part of an on-going study in the Department of Psychiatry. 
Investigated was mood symptom manifestation across the menopausal stages and 
association with endocrinological assessments. This was accomplished with the 
use of standardized, validated, reproducible, diagnostic data. Database descriptive 
analyses and correlational statistics were used to assess demographic description 
of subjects and preliminary association of mood and menopausal stage and 
reproductive hormones. Due to the small sample size of the on-going study, the 
strength of correlations ranged from insignificant to inconclusive. Thus it was 
concluded that further research and a larger sample size would be needed to 
make strong correlations between menopause and the exacerbation of bipolar 
disorder symptoms.  
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Abstract 
This project investigated the relationship between bipolar disorder and menopause in 41 
research participants at the University of Massachusetts Medical School, as part of an on-going study in 
the Department of Psychiatry. Investigated was mood symptom manifestation across the menopausal 
stages and association with endocrinological assessments. This was accomplished with the use of 
standardized, validated, reproducible, diagnostic data. Database descriptive analyses and correlational 
statistics were used to assess demographic description of subjects and preliminary association of mood 
and menopausal stage and reproductive hormones. Due to the small sample size of the on-going study, 
the strength of correlations ranged from insignificant to inconclusive. Thus it was concluded that further 
research and a larger sample size would be needed to make strong correlations between menopause 
and the exacerbation of bipolar disorder symptoms.  
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Introduction 
During transitional menstrual periods there is an increase or alteration of normal endocrine 
levels which often leads to a flux in mood. This change takes place in women as a result of a slew of 
neurochemical and endocrinological changes that take place in the brain and bodies of women on a 
monthly basis. At the same time, women who have been diagnosed with bipolar disorder, already 
experience mood fluctuations that are deviations from the norm due to the manic and depressive 
episodes that characterize their syndrome. It is hypothesized that during transitional menstrual periods, 
women with bipolar disorder are more susceptible to the exacerbation of their bipolar symptoms. This 
exacerbation is a result of the bipolar symptoms being compounded with the rising and decreasing 
endocrine levels coupled with neurochemical alterations stemming from menstrual transition. The 
purpose of the present investigation is to validate the hypothesis by making correlations between mood 
rating scales, menopausal stage, age and the bipolarity index. 
 
Background 
The reproductive life for a woman is marked by the presence of the menstrual cycle. Menarche 
(onset of menses) begins during puberty. Unless pregnancy occurs, the menstrual cycle continues until 
menopause. The cycle periodicity is approximately 28 days, and culminates with the shedding of the 
uterine lining. However, as a woman approaches menopause, the cycle becomes irregular and fertility 
decreases. This naturally occurring physiological process is associated with an ultimate decrease in 
gonadal hormone levels, specifically estrogen and progesterone. Menopause is defined as one year 
since the final menstrual period (Curie, 2006). This is a clinical diagnosis and is not reliably assessed by 
hormonal levels as they vary considerably through the transition.  The average age of menopause in the 
United States is 51 (Benazzi, 2000).  
 
The Menstrual Cycle 
To better understand the effects of menopause on women, one has to understand how the 
menstrual cycle functions. This 28 day cycle is comprised of three different phases: follicular phase, 
ovulatory phase, and luteal phase.  Figure 1 shows an illustration of the menstrual cycle phases and 
common length variations. Variations in cycle length occur as a result of the lengthening of the follicular 
phase (light blue).  Ovulation begins by stimulation of the ovarian follicles to produce an increase in 
estrogen production in granulosa cells. The body responds to the estrogen rise by stimulating the 
pituitary gland to release luteinizing hormone (LH), responsible for ovulation. This process is referred to 
as the ovulatory phase (blue arrow in the figure). The lining of the womb thickens as progesterone is 
produced in the corpus luteum, marking the commencement of the luteal phase (dark blue). Failure of 
fertilization induces a decline in both progesterone and estrogen, while increasing the amount of 
follicular stimulating hormone (FSH). Menstruation then occurs due to the fluctuation in endocrine 
levels (Currie, 2006). The follicular phase serves as the body’s mechanism for preparing for pregnancy 
with the aid of the endocrine system. Menstruation occurs when the body disposes of the nutrient rich 
lining that would support an embryo, marking the end of the body’s preparation for conception. 
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  Figure 1: Diagram of the Menstrual Cycle Phases and Length Variation   
 
Figure 2 shows a graphical representation of the complex endocrine and physical changes 
occurring throughout the menstrual cycle. The act of menstruating, often called menses, marks the first 
day of the cycle and the first phase of the cycle: the follicular phase. When the sloughing of the uterine 
lining (menses) ceases, the levels of estrogen, specifically estradiol (E2), soon increase.  Menstruation 
lasts an average of three to seven days to expel the uterus collapsed. Levels of estradiol continue to 
increase throughout the follicular phase. As the endometrium (lining of the uterus) re-thickens, follicles 
in the ovaries develop and mature. A follicle houses the oocyte, or “egg” that contains the woman’s half 
of the genetic material for her offspring.  Approximately from day 7 to day 14, one follicle becomes 
dominant and matures into a viable oocyte, while the rest become polar bodies and degenerate. Once 
mature, an LH surge induces the follicle to burst and release the egg, a process called ovulation. After 
ovulation the luteal phase begins. The follicle responsible for ovulation morphs into the corpus luteum, 
which functions to produce progesterone. Meanwhile, hair-like structures termed fimbria maneuver the 
egg from the ovary into the fallopian tubes to await fertilization. Failure to obtain proper implantation 
onto the uterine wall causes a decline in estradiol levels. The drop in estrogen levels reciprocates a rise 
in the release of FSH and LH hormones. However, the body utilizes a feedback mechanism to decrease 
the levels of FSH and LH once sufficient progesterone is secreted to signal an increased production of 
estrogen. Thus, the body begins to prepare for another menstrual cycle (Ferin, 1993). 
Shown are three example cycle lengths of 25, 28, and 35 days, and the 
length of the three main phases, menses (red), follicular phase (light 
blue), and luteal phase (dark blue) (Ferin, 1993). 
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Figure 2: Diagram of Hormonal Changes in the Menstrual Cycle 
 
  The egg cell count (oocytes) in women begins to decline starting at birth. At menopause the egg 
cell count is drastically reduced. Eventually the ovaries cease to produce estrogen and progesterone, 
resulting in a difference in the ratio of progesterone and estrogen endocrine levels relative to that of 
FSH and LH; progesterone and estrogen levels decrease, while the FSH and LH levels increase. Upon 
completion of the menopausal transition, menstrual cycle stops and a woman is no longer fertile (Currie, 
2006).  
 
Menopause 
Menopausal diagnosis is based on changes in menstrual cycle frequency. Menopause is divided 
into three stages, including: i. late pre-menopause (late reproductive years when fertility declines); ii. 
early and late peri-menopause combined (commonly referred to as menopause); iii. early post-
menopause.   
Menopausal symptoms are common and may include: hot flashes (sudden warmth sensations 
which may cause profuse sweating), night sweats, palpitations, insomnia, weight gain, breast 
tenderness, and headaches. Women usually do not experience all these symptoms at once, as the 
symptoms may appear throughout any of the stages (Currie, 2006). The criteria for distinguishing the 
stages of menopause were established in July of 2001 during the Stages of Reproductive Aging 
Workshop detailed in the STRAW section of this paper.  
The reproductive years may be described as pre-menopause, and include menarche to the onset 
of peri-menopause. When menstrual cycle frequency naturally becomes irregular, it marks the onset of 
Shown are the main hormonal changes throughout the cycle, 
relative to the status of the egg (lower diagram) (Ferin, 1993). 
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peri-menopause. The term menopause is reserved for the occurrence of the last menstrual cycle, often 
called climacteric, defined as one year after last menstruation.  The conclusion of menopause marks the 
beginning of post-menopause, lasting the remainder of a woman’s life.  Menopausal symptoms may be 
experienced postmenopausal such as vaginal dryness and hot flashes (University of Rochester Medical 
Center, 2012).  
 Ovarian composition undergoes significant endocrinological changes that lead up to 
reproductive senescence and the cessation of the menses. Etiologically, the reduction in oocytes and the 
depletion of follicles in the ovary ultimately change the morphology of the ovary. Figure 3 shows a 
histological representation of the change in ovarian tissue and follicles, before and after menopause.  
The left panel shows circular formations that simulate the ovary of a baby that is one year of age. The 
middle panel represents the ovary throughout a female’s fertile reproductive ages. The last panel 
represents the ovary depleted of its follicular reserve after menopause.  
 
 
 
Figure 3: Diagram of Ovarian Histology Before and After Menopause 
 
Stages of Reproductive Aging Workshop (STRAW) 
On July of 2001, the stages of menopause were classified by the Stages of Reproductive Aging 
Workshop (STRAW) sponsored by the American Society of Reproductive Medicine (ASRM) and the North 
American Menopause Society (NAMS). The workshop served to set forth a series of criteria for 
identifying the staging system, characterizing the aging of the female reproductive life. The staging 
system divided a woman’s reproductive life into seven stages. The commencement of menopausal 
transition is identified by a change in the menstrual cycle of approximately 7 days. The STRAW criteria 
also took into consideration both the frequency and the length of menstrual cycles, which are associated 
with fluctuations in estradiol and progesterone. At the time, researches chose FSH as the most suitable 
marker associated with the onset of the peri-menopause (Soules et al., 2001).  
The data was based on studies of endocrine changes throughout the menstrual cycle in 77 study 
subjects. The study consisted of measuring serum hormone levels three times a week on women who 
were in their reproductive ages to peri-menopausal stages (Soules et al., 2001).  
Shown are diagrams of the ovary at year-1 (left panel), reproductive 
years (middle panel), and post-menopause (right panel) (Ferin, 1993, 
page 94.) 
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Figure 4: STRAW:  Stages & Nomenclature of Normal Reproductive Aging in Women 
 
During reproductive years, menstrual cycling has a regular frequency and FSH levels 
slightly fluctuate throughout the cycle. FSH levels rise above reproductive levels during the 
transition into menopause. Levels of FSH remain elevated throughout peri-menopause and post-
menopause. Figure 4 above presents the physical changes that ensue as a result of transitioning 
through different menstrual phases up to post-menopause. Other endocrine levels that declined 
while transitioning into menopause were inhibin-B and anti-Mullerian hormone (Hale et al., 
2007). 
 
Symptomatic Treatment of Menopause 
Throughout the peri-menopausal and early post-menopausal years, women may suffer from 
vasomotor symptoms consisting of hot flashes and night sweats. Vasomotor symptoms occur during 
abrupt dilations of blood vessels near the epidermis. Statistics show that hot flashes affect 60-84% of 
menopausal women in the United States (Currie, 2006).  Menopause may also be associated with 
vaginal dryness, sexual changes, urinary discomfort, sleep disturbance, mood swings, and cognitive 
disturbances (Nelson et al., 2005).  
The menopausal transition is a natural reproductive change in a woman’s life. Thus, for example, 
the Mayo Clinic notes that no treatment exists for menopause; however, menopausal symptoms can be 
disruptive. So medication management is often utilized. One of the most effective treatment 
approaches is the administration of estrogen. Hormone therapy (HT) may include estrogen and/or 
The stages are characterized by the length of the menstrual cycle. Irregularities in the 
menstrual transitioning are induced by a rise in FSH endocrine levels experienced 
during late reproductive ages (Soules et al., 2001). 
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progesterone. Estrogen is considered to be the most effective treatment for menopausal symptoms. 
Antidepressants such as selective serotonin reuptake inhibitors (SSRIs) have also shown to decrease hot 
flashes and improve depressive symptoms. However, doctors recommend using only low dosages of 
antidepressants, enough to relieve menopausal symptoms (Mayo Foundation for Medical Education and 
Research, 2011). Estrogen is an evidence-based treatment for vaginal dryness and discomfort and 
improves bone mineral density (Mayo Foundation for Medical Education and Research, 2011).  
 
Bipolar Disorder 
The Diagnostic and Statistical Manual of Mental Disorders, Edition IV (DSM-IV) defines bipolar 
disorder as a mood disorder characterized by the incidence of mania or manic episodes and depression 
or depressive episodes. Mania refers to the presence of atypically elevated energy, cognition or mood 
levels. If the mood episode is slighter than typical mania, the DSM-IV refers to this sate as hypomania. 
Those experiencing manic episodes are susceptible to depressive episodes, with the possibility of a 
mixed state in which characteristics of both episodes appear simultaneously. In some cases the 
alternation between the states of mania and depression occur quickly. This is known as rapid-cycling. In 
other instances, individuals can experience periods of normal mood; dividing the manic and depressive 
episodes. When the severity of manic episodes increases, individuals may display psychotic symptoms, 
coupled by delusions.  
 
Components of Bipolar Disorder 
There are four main components to bipolar disorder that present themselves in different 
intensities and in turn define a subtype based on their prevalence. The hallmark of bipolar disorder is 
the manic episode. The severity of which is often used to determine the classification of the disorder. 
Mania 
 The term mania refers to an interval of elevated mood, sometimes manifesting itself as 
euphoria. Individuals experiencing mania frequently exhibit and increase in energy, with decreased need 
for sleep. Some individuals only sleep for a few hours while some may last for days without sleep 
(American Psychiatric Association, 2000). Other common symptoms of mania are racing thoughts and 
pressured speech (Mayo Clinic, 2012). Severity of a manic episode may be monitored by scales such as 
the Young Mania Rating Scale (Young, Biggs, Ziegler, & Meyer, 1978).  
Criteria for Manic Episode 
 A manic episode is a period marked by irregularity and continual irritable, expansive and 
elevated mood, persisting for a minimum of one week. The duration of the episode becomes less 
important if hospitalization is required as the severity of the episode trumps the durative component of 
the criteria (American Psychiatric Association, 2000). During a manic episode, an individual may 
experience exaggerated self-esteem or grandiosity, in addition to decreased need for sleep (in which 
case the individual feels rested with far less than eight hours of sleep). Individuals may also be more 
talkative, distractible, or experience flight of thoughts. Lastly, the individual may be involved in goal-
directed or pleasurable activities, with the time spent on these activities being disproportionate to time 
spent on other activities. To meet the criteria of a manic episode, three or more of the aforementioned 
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symptoms must have endured (four if the mood displayed was irritability). The other caveat is that 
persistence of the symptoms must be significant to meet the criteria (American Psychiatric Association, 
2000). 
 It should be noted that the criteria for a mixed episode are not the same as the criteria for 
mania. The symptoms of a manic episode must be independent of any medication or narcotic. In 
addition, the symptoms have to be severe enough to interrupt or preclude the completion of everyday 
activities or result in hospitalization or psychosis (American Psychiatric Association, 2000). 
Hypomania 
Hypomania is a less severe manifestation of mania. While these symptoms appear to be the 
same as those of mania, their expression is mild to moderate.  
Criteria for Hypomanic Episode 
 The criterion for a hypomanic episode is very similar to that of the manic episode with a few 
alterations. Different to a manic episode, a hypomanic episode requires only four days of mood 
elevation, expansiveness or irritability. The criteria for hypomania require that during a hypomanic 
episode, the same amount of symptoms must last and persist significantly, analogous to the criteria of a 
manic episode. While the severity of the symptoms is less intense, the symptoms of hypomania are the 
same as mania in definition and classification. One of the most notable differences between mania and 
hypomania is that the symptoms are not debilitating, thus they do not prevent the individual from 
completing tasks that they unusually would. Nonetheless, the symptoms are obvious enough that 
bystanders can notice the difference in the individual’s behavior. Once again these symptoms may not 
be induced by drugs to count as a hypomanic episode. 
 
Depression 
A depressive episode is characterized by feelings of sadness and or anhedonia (loss of interest in 
activies) plus at least five of nine other symptoms. These include suicidal ideation, increased sleep and 
loss of appetite. Individuals may also experience fatigue and anxiety which is a common comorbid 
diagnosis.  
Major Depressive Episode Criteria 
The episode must last least two weeks and cause dysfunction. Psychosis may occur, such as 
delusions or hallucinations (Mayo Clinic, 2012). Other symptoms include being depressed for a majority 
of the day, insomnia or hypersomnia and sever weight loss. Additionally, individuals may also experience 
psychomotor agitation and feelings of worthlessness, coupled by incongruous feelings of guilt. Those 
experiencing this level of depression may experience an inability to concentrate and incessant thoughts 
of death. To be classified as a depressive episode, five (or more) symptoms must be present and persist 
in the aforementioned two week period in addition to altering the individual’s functionality. An ongoing 
medical condition or substance abuse cannot be the source of these symptoms. The symptoms must be 
clinically significant meaning that they are debilitating and preclude the individual from performing 
everyday activities. The criterion for a mixed episode does not fit these symptoms.  
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Bipolar Types 
Bipolar disorder is classified by severity of mood elevation, namely, Bipolar I, Bipolar II and not 
otherwise specified (NOS).   A definitive number of subtypes of bipolar disorder have yet to be 
determined. However, the DSM-IV-TR recognizes four subtypes; three specified and one, not. The three 
specified subtypes are Bipolar I and II Disorder and NOS. The last subtype is referred to as “Bipolar Not 
Otherwise Specified (NOS)” (American Psychiatric Association, 2000). 
Bipolar I 
To be diagnosed with Bipolar Disorder I (BD I), one must experience one or more manic 
episodes. This subtype is characterized by severe, potentially perilous manic episodes and mood swings 
that may place strain on relationships, and require hospitalization. Such a severe manic episode may 
also result in psychosis. In addition, the individual cannot manage at school or work. Bipolar I is the most 
debilitating of the acknowledged subtypes on the continuum (Mayo Clinic, 2012). An episode of 
depression is not necessary for Bipolar I diagnosis, but usually occurs. 
Bipolar II 
Bipolar II (BD II) is characterized by the same symptoms as Bipolar I but the appearance of said 
symptoms are far more mild, and as such the individual with Bipolar II is able to carry on and function in 
daily life. One difference between Bipolar I (longer than one week) and II (more than four days) is the 
duration of episodes. Also, for a diagnosis of BD II, one needs to have experienced a major depressive 
episode. Those with BD II tend to experience longer periods of depression than hypomania (Mayo Clinic, 
2012). 
Table 1 the main mood and behavioral changes used to diagnose mania and depression. Table 2 
below shows the main neuropsychological profile of bipolar patients, especially the difference between 
depression (middle column) and mania (right column). 
Bipolar Disorder Not Otherwise Specified (BD-NOS) 
The diagnosis of bipolar disorder is not a simple task. When a diagnosis does not fit into one of the 
specified subtypes of bipolar disorder, the disorder falls into the category of NOS. Bipolar Disorder Not 
Otherwise Specified (NOS) is diagnosed when an individual exhibits symptoms of the subtypes of bipolar 
disorder. However, classification may not fall into a specific subtype because the symptoms not meet 
the subtype criteria fully. This may be a result of a preexisting medical condition or substance abuse 
(American Psychiatric Association, 2000). 
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Table 1: Diagnosis for Mania and Depression 
Symptoms of mania or manic episode: Symptoms of depression or a depressive episode: 
Mood Changes: 
• A long period of feeling “high,” or an overly 
happy or outgoing mood 
• Extremely irritable mood, agitation, feeling  
‘”jumpy” or “wired” 
Behavioral Changes  
• Talking very fast, jumping from one idea to 
another , having racing thoughts 
• Being easily distracted 
• Increasing goal-directed activities, such as 
taking on new projects  
• Being restless 
• Sleeping little 
• Having an unrealistic belief in one’s abilities 
• Behaving impulsively and taking part in a lot of 
pleasurable, high-risk behaviors, such as 
spending sprees, impulsive sex, and impulsive 
business investments 
Mood Changes: 
• A long period of feeling worried or empty  
• Loss of interest in activities once enjoyed 
Behavioral Changes  
• Feeling slowed down 
• Having  problems concentrating, 
remembering and making decisions 
• Being restless and irritable 
• Changing eating, sleeping or other habits 
• Thinking of death or suicide, or attempting 
suicide  
 
 
Table 2:  The Main Neuropsychological Profile of Bipolar Patients 
 
 
 
Cognitive Domain  Bipolar Depression Euthymia Mania 
Set-shifting and (or) concept formation  ↓ ↓↓ ↓↓ 
Verbal fluency ↓ ↓ • ↓ 
Decision making  — ↓ • ↓ 
Planning and (or) problem solving  ↓ ↓ ↓↓ 
Nonverbal intelligence   ↓ • • • ↓ 
Sustained attention  ↓ ↓↓↓ ↓↓ 
Verbal memory–delayed recall  ↓ ↓ ↓ 
Visual memory  ↓ ↓ • ↓ 
↓•= Reduced and (or) impaired, compared with healthy control subjects; • = no change, compared with healthy control subjects. Each symbol 
denotes the finding from one study.  
Shown are the diagnostic symptoms for mood episodes of bipolar 
disorder (National Institute of Mental Health (NIMH), 2009). 
Shown are the various cognitive functions altered in bipolar disorder 
(first column) and the extent each is affected in depression (middle 
column) and mania (right column) (Mahlo, 2004). 
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Bipolar Disorder, Menopause, and Dietary Supplements 
 The risk of unipolar depression increases during menopause. Potential relationships between 
BD I, BD II, and menopause together are relatively unstudied.  Three reproductive phases, premenstrual, 
postpartum, and peri-menopause are characterized by a decline in estrogen and progesterone levels. 
These are associated with increased risk of depressive symptoms due to hormonal fluctuations. The 
hormone levels tend to decrease after the following occurrences: (i) the luteal phase of the regular 
menstrual cycle, (ii) labor, and (iii) the onset of irregular ovulation (actually menstruation) marking peri-
menopause (Payne, 2007). 
BD is a lifelong illness with no cure; however, recurrent symptomatic mood swings can be 
alleviated with proper treatment.  It is hypothesized that bipolar disorders originate from an overactive 
cell-signaling pathway (Stoll, 1999).  Suppression of the signal transduction pathways can in turn weaken 
the likelihood for bipolar disorders.  Suppression may be achieved by medications which function to 
inhibit these neuronal membrane pathways, and are common treatments administered to individuals 
experiencing severe mood swings (Stoll, 1999).  However, not enough evidence exists to prove or 
disprove this theory. Most treatments have to be administered on a long-term basis to reduce symptom 
severity. Treatments include mood stabilizing medications such as lithium, anticonvulsants for example 
valporic acid, or divalporex sodium (Depakote), or antipsychotics. Many anticonvulsants, which treat 
seizures, have FDA approval to be used as treatment for bipolar disorder, and as an alternative to 
lithium (National Institute of Mental Health, 2009).  
Research suggests that omega three and six fatty acids exhibit a similar function of attenuating 
the signal transduction pathways overactive in BD (Stoll, 1999); thus, dietary supplements can serve as 
an adjunctive treatment for bipolar disorder.  Additional studies revealed that when treatments are 
coupled with docosahexaenoic acid (DHA), the consumption of the omega three fatty acids are essential 
for neuronal development (Simopoulos, 1991). Omega three fatty acids reside within the brain in large 
concentrations, leading researchers to believe the fatty acids are associated with cognitive and 
behavioral function. However, the benefits of omega-three-fatty-acid-intake to improve bipolar disorder 
symptoms remain inconclusive (University of Maryland Medical Center (UMMC), 2011).  
 
University of Massachusetts Medical School – Dr. Wendy Marsh’s Study 
Dr. Wendy Marsh at the University of Massachusetts Medical School (UMMS) is the principal 
investigator (PI) on a grant entitled “The Impact of Peri-menopause on Bipolar Disorder”.  The study is a 
five year career development award being conducted in the Department of Psychiatry.  The research is 
designed to elucidate the course of bipolar disorder through peri-menopause in relation to menopausal 
phase and endocrinological status. The study is strictly observational. 
Dr. Marsh targets a sample of 75 women, treated for bipolar disorder, who voluntarily 
participate in the study.  Out of the sample, 25 will have experienced early peri-menopause, 25 will have 
experienced late-menopause, and another 25 will have experienced early post-menopause. Participants 
will record their mood symptoms for a total period of four months, equivalent to five clinical visits. Visits 
are completed on-site or through a phone interview (Marsh, 2008). To date, a total of 41 women have 
participated in the study.  Of these 41 participants, 25 were peri-menopausal, and 14 were post-
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menopausal. Of these subgroups, one peri-menopausal and another post-menopausal subject were lost 
to follow up.  
Initial visits last two to three hours, and begin with a detailed informed consent.  Mood and 
reproductive assessments (both administered self and by trained practitioner) are completed together 
with an endocrinological assessment (including an FSH and estradiol blood draw). The forms are 
discussed in the Methods section: Protected Health Information Form (PHI), Demographics Form, 
Clinical Monitoring Form (CMF), Montgomery-Aspberg Depression Rating Scale (MADRS), Young Mania 
Rating Scale (YMRS), Menstrual History Form, Greene Climacteric Scale, and Affective Disorders 
Evaluation (ADE).  Subjects are also trained in the use of the daily mood tracking software 
ChronoRecord.  At successful completion of the initial visit subjects are compensated with $20.00. 
Follow-up visits are conducted either over 2 months between menstrual cycles, or at the time of 
a subject’s menstrual cycle if less than 6 weeks form prior visit. If post-menopausal, visits are are 
completed on a monthly basis. The duration of the follow-up visits is roughly thirty minutes where 
participants only complete the CMF, MADRS, YMRS, the blood panel and return of the previous months 
ChronoRecord mood data. A total of $30.00 is received at completion of the fifth (final) visit.  
Mood symptoms and hormonal data acquired for each subject are then reviewed and inputted 
into the REDCap database. Analysis of the information housed within the database will aid researchers’ 
abilities to support or reject various hypotheses related to a correlation between menopause and BD.  
Specifically, researchers are investigating whether higher rates of depression are accompanied by a 
substantial increase in FSH levels present during late menopause (Marsh, 2008). 
 
Forms Utilized and Their Significance 
 
Protected Health Information (PHI) 
The “Protected Health Information (PHI)” form contains the information that is to be separated 
from the subjects visit charts to de-identify the subjects. This information includes the subjects first and 
last name, date of birth, physical and e-mail addresses, and preferred phone numbers. This information 
is kept in a binder separate from the visit records and is used to contact the subjects about their 
appointments. This form is filled out only at the first visit. 
 
Affective Disorders Evaluation (ADE) 
The “Affective Disorders Evaluation (ADE)” form is filled out by the physician on the first visit. 
The ADE is a standardized assessment form based on DSM -IV criteria with which the physician 
determines the subjects’ diagnosis. 
Due to the complexity of mood disorders, it is necessary to glean as much information as 
possible to gain the clearest picture of the subjects’ history and preset illnesses. This is important, as the 
uniqueness of the subjects’ background may be crucial in determining the correct diagnosis and preset 
illnesses. The ADE will allow the physician or clinician to make these assessments about the subjects’ 
disorders from a diagnostic standpoint (See Appendix B).  
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Demographics 
Also completed at the first visit is the “Demographics Form” that contains information about the 
subject’s socioeconomic status. This information includes the subject’s marital status, occupation, 
annual income and other information. The possible selections for this form are predetermined and 
designated by numbers one through eight (Refer to Appendix C).  
 
Greene Climacteric Scale 
The “Greene Climacteric Scale” assesses menopausal symptoms, dividing them into three 
categories: mild, moderate and severe. The scale assesses the rate and force of the subjects’ heartbeat. 
It assesses the subjects’ tension and nervousness, whether they are experiencing difficulty sleeping or if 
they are excitable. The form inquires whether the subject is experiencing panic attacks, difficulty 
concentrating and level of lethargy. The scale also evaluates the subjects’ level of interest in activities, 
depression levels, crying spells and irritability. Furthermore the form gauges whether the subject is 
feeling dizzy, faint, and tight in the head or body and numbness or tingling in the body. The scale also 
measures headache severity, muscle and joint pain and loss of feeling in extremities. Lastly, the Greene 
Climacteric Scale assesses the severity of the subjects’ hot flushes, night sweats and potential loss of 
interest in sex (See Appendix D). 
 
FSH and Estradiol Blood Panel  
At each clinical visit the subjects’ blood is drawn and sent to the lab where it is tested for FSH 
and Estradiol levels (See Appendix E).  
 
Menstrual History 
The “Menstrual and Medical History” form is a self-completed form filled out by the subjects at 
the first visit (See Appendix F and G).  
 
Young Mania Rating Scale (YMRS) 
 Also completed at each subject visit is the “Young Mania Rating Scale (YMRS)”. Both the YMRS 
and the MADRS assess mood. However, the YMRS was developed based on the central symptoms of 
mania associated with bipolar disorder. Specifically, the YMRS assesses the spectrum of mood elevation 
symptoms from mild to severe. As a result, this scale complements the MADRS (See Appendix H).  
 
Montgomery-Aspberg Depression Rating Scale (MADRS) 
 Completed at all five visits is the “Montgomery-Aspberg Depression Rating Scale (MADRS)”. 
Adopted in 1979, the MADRS is a depression scale created to measure incremental alterations in the 
subjects’ mood. This scale is able to measure changes in mood over any time period. The MADRS is a 
highly focused and fine-tuned decedent of the Comprehensive Psychopathological Rating scale (CPRS). 
The CPRS was reduced from its 65 items down to the ten most essential items most relevant to the 
diagnosis of depression. These are the 10 symptoms assessed in the MADRS: apparent sadness, 
reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, inability to 
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feel, lassitude, and a propensity for both pessimistic and suicidal thought (Burns, Lawlor, & Craig, 
2001)(See Appendix I). 
 
Clinical Monitoring Form (CMF) 
 The “Clinical Monitoring Form” is a clinical evaluation and tracing instrument intended to make 
highly effectual the process of keeping record of differential diagnostic information, essential to making 
clinical assessments. There are four main purposes of the CMF. The primary goal of the CMF is to 
establish the subjects’ present clinical status. The secondary goal of the CMF is to deliver a methodical 
follow-up to enable ongoing valuation. 
 
ChronoRecord  
 Based on the ChronoSheet from the 1970’s, the ChronoRecord is a longitudinal analysis software 
used to measure subjects’ menstrual cycle sleep pattern and mood. This data can then be used to help 
clinicians treat mood disorders, such as bipolar disorder. In addition the software also keeps records of 
the medications that the subjects are taking to treat symptoms. 
 
Methods 
Biology students of Worcester Polytechnic Institute (WPI) approached physician Wendy Marsh 
M.D.M.S. of University of Massachusetts Medical School (UMMS) to inquire if there was ongoing 
research that she was involved in that the students could participate in. She had a grant to study the 
impact of peri-menopause on the clinical course of bipolar disorder.  
 
Internal Review Board (IRB) Approval and Physical Examination  
In order to begin research at the University, the students were required to receive Internal 
Review Board (IRB) approval at UMMS. To do this the students had to participate in human subject 
training since this project involves research with human subjects. The training involved a web based 
course and test (CITI website) that took approximately five hours to complete. Each student was 
required to read the modules associated with the test in order to answer pertinent questions. To pass 
the training and be qualified for IRB approval the students had to the pass the exams with an average of 
80%. This training is required of volunteer in staff to teach them the fundamentals of research ethics 
and protocols outline CITI courses. This was important because the students would be working with 
highly sensitive information regarding the subjects, such as medical records, and additional information 
that would be entered into a database.  
The other requirement for working with human subjects on the campus was to become 
volunteers of the Department of Psychiatry at UMMS. To do this the students had to have a physical 
examination to make sure that the students were free of tuberculosis, hepatitis and HIV. This type of 
physical examination is required by any employee of the medical staff at UMMS. 
 
REDCap Database 
REDCap stands for Research Electronic Data Capture. Developed by the University of 
Vanderbuilt, the database software is used by researchers at the University of Massachusetts Medical 
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School (Harris, 2009). The software is a web-based interface. The user interface is very simple and 
intuitive. The software lends itself nicely to producing forms with custom fields that allow the data 
collectors to collect` information specific and pertinent to their research. For security purposes, the 
subject’s research records are de-identified by removing the protected health information like name and 
date of birth from the data and resolve to numbering the records. For further security measures, all of 
the data entry was completed on campus in a locked office, to maintain the privacy of the subjects as 
enforced by the protocols outlined in human subjects training and HIPPA. 
The actual data base was a digital version of the medical records that were built upon each visit 
of the subjects. The forms in each patients chart included the following forms: 
1. Protected Health Information (PHI) 
2. Demographics 
3. Menstrual and Medical History 
4. Affective Disorders Evaluation (ADE) 
5. Clinical Monitoring Form (CMF) 
6. Young Mania Rating Scale (YMRS) 
7. Montgomery-Aspberg Depression Rating Scale (MADRS) 
8. Greene Climateric Scale 
9. FSH and Estradiol blood panel data 
Other data not included in the REDCap databases include:  
1. Mood Attribution Answers (open ended questions answered by the patient and audio recorded 
by the physician) 
2. ChronoRecord (a daily mood monitoring form software given to the subjects) add website 
address 
 
Each subject participates in the study for a period of four to five months and completes a total 
of five visits. The first baseline visit is the longest, lasting for three to four hours. This visit encompasses 
all of the aforementioned forms. Subsequent visits last an approximate duration of twenty to thirty 
minutes; covering the CMF, YMRS, MADRS, and blood panel. Some of the postmenopausal subjects 
complete their subsequent visits via a telephone call as a blood panel is unnecessary. The blood panel is 
not necessary for postmenopausal subjects as women's hormones remain relatively constant after they 
have gone through menopause. Researchers Curry and Ortiz, entered medical records for subjects 304 
through 341, each containing individual sub-folders for one to five subsequent visits. Below is a table of 
the data entered into the REDCap database.  
There is a $50.00 compensation given to the subjects that participate in the study. They receive 
$20.00 at the first visit and $30.00 at the last visit. At UMass Medical University the IRB Board has strict 
policy regarding subject’s compensation as to adhere to the protocols and mores outlined in the human 
subjects training. Therefore the subjects are not compensated handsomely, to avoid immoral instances 
such as coercion. 
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Results 
 
Demographic Form Data 
Data from the forms in the subjects’ charts were collected over the duration of the study and 
inputted into the REDCap database. 
 
Figure 5: Bar Chart of the Subjects’ Menopausal Stage 
 
 Figure 5 above shows 25 subjects were peri-menopausal (early and late combined) and 14 
subjects were post-menopausal (See Appendix A).  
 
 The figures below display data from the fields found on the Demographics Form. The first field 
on the demographics form is the highest level of education completed by each subject in the study and 
the data is shown in Figure 6 below. 
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Presented is the menopausal stage distribution of the subjects 
participating in the study.  
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Figure 6: Bar Chart of the Levels of Education Completed by Subjects 
 
Each of the numerical value on the scale represents a level of education: 
1. Less than the seventh grade 
2. Seventh grade – ninth grade 
3. Partial High School 
4. High School Diploma or GED 
5. Some college (at least one year) 
6. Technical School or Associates Degree 
7. College Diploma (Bachelor’s Degree) 
8. Graduate or Professional Degree 
 
As seen in the Figure 7 below, there one subject that partially completed their high school education. 
Seven of the subjects earned a high school diploma, or equivalent such as a GED. Twelve of the subjects 
completed at least one year of college. Five of the subjects attained either a technical certification or an 
associate’s degree. Six of the subjects earned a college diploma. None of the subjects completed 
graduate or professional education. One subject dropped. 
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Shown are the levels of education completed by the subjects of the 
study. Above each bar is the number of subjects that completed the 
respective level of education shown according to the scale. 
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Figure 7: Bar Chart of Race/Ethnicity of Subjects 
 
Each of the numerical value on the scale represents a race or ethnicity: 
1. American Indian or Alaska Native 
2. Asian 
3. Hispanic or Latino 
4. Black or African American 
5. White, Non-Hispanic 
6. Native Hawaiian or Pacific Islander 
 
There was one american indian subject, one hispanic subject and thirty-seven white, non-hispanic 
subjects. One of the subjects as aforementioned was lost to follow-up.  
 
 
0
5
10
15
20
25
30
35
40
Blank 1 2 3 4 5 Dropped
N
um
be
r o
f S
ub
je
ct
s 
Race/Ethnicity 
0
2
4
6
8
10
12
14
16
18
20
N
um
be
r o
f S
ub
je
ct
s 
Marital Status 
Shown is the ethnicity of the subjects participating in the study. 
Numerical values on the x-axis denote the subjects’ given ethnicity.  
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Figure 8: Bar Chart of the Marital Status by Subjects 
 
Each of the numerical value on the scale represents a marital status: 
1. Never Married (Never lived as Married) 
2. Married 
3. Living as Married 
4. Separated/No longer living as married 
5. Divorced 
6. Widowed 
 
As presented in Figure 8 above, there were three subjects that had never been married. Nineteen of the 
subjects were married. One of the subjects was living as married. Three more of the subjects had been 
seperated from there significant other. Twelve of the subjects were divorced. One of the subjects had 
been widowed. 
 
 
Figure 9: Bar Chart of the Current Employment Status Subjects 
 
Each of the numerical value on the scale represents an employment status: 
1. Full-time 
2. Part-time for pay 
3. Homemaker 
4. Student 
5. Volunteer 
6. Incarcerated 
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Presented is the employment status of the subjects participating in the 
study. 
Shown is the employment status of the subjects participating in the study. The 
majority of the subjects identified themselves as volunteers or as individuals 
working for part-time pay.  
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7. Disabled 
8. Leave of Absence 
9. Unemployed 
10. Retired 
11. Other 
 
As presented in Figure 9 above, six of the cadidates were emplyed full time. Eight of the subjects worked 
part-time for pay. Six other subjects were homemakers. None of the subjects were students at the time 
of the study. Six of the subjects qualified for disability. One of the subjects was unemployed. 
 
Figure 10: Bar Chart of the Occupation of the Subjects 
 
Each of the numerical value on the scale represents an occupation type: 
1. Executive manager 
2. Professional 
3. Business/Tech Manager 
4. Arts or Entertainment 
5. Administrative Personnel 
6. Technical Personnel 
7. Clerical 
8. Skilled Manual 
 
As displayed in Figure 10 above, seven of the of the subjects left the occupation field blank. One was an 
executive professional. Nine of the subjects were professionals. Another subject was a business/tech 
manager. Two of the subjects were in the arts or entertainement industry. Four of the subjects were 
administrative personnel. One of the subjects was a technical personnel. Another nine of the subjects 
held clerical positions. Lastly eight of the subjects were skilled laborers. 
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Displayed is the occupation of the subjects participating in the study. 
Most subjects partook in a professional or clerical occupation.  
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Figure 11: Bar Chart of the Household Income Received by Subjects 
 
Each of the numerical value on the scale represents a household income range: 
1. Less than $10,000 
2. $10,000-$19,999 
3. $20,000-$29,999 
4. $30,000-$39,999 
5. $40,000-$49,999 
6. $50,000-$74,999 
7. $75,000-$99,999 
8. $100,000-$149,999 
9. $150,000-$199,999 
10. $200,000 or more 
 
As displayed in Figure 11 above, one subject  left the income field blank. Five subjects enjoyed a 
household income of lest than $10,000 per anum. Eleven of the subjects enjoyed a household income 
range beween $20,000 and $29,999. Two subjects had a household income range of $40,000-$49,999. 
Three enjoyed a household income range between $50,000 and $74,999. Four subjects had household 
incomes of $75,000-$99,999 while another four enjoyed household incomes between $100,000 and 
$149,999. Lastly, one of the subjects enjoyed a household income range beween $150,000 and 
$199,999. 
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Exhibited is the household income of the subjects participating in the 
study. A good portion of the subjects received $20,000-$29,999.  
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Correlations and Data Analysis 
 Taking the empirical data from the REDCap database, correlations were made in an effort to 
validate findings found in literature. Correlations were made using the Microsoft Excel Data Analysis 
ToolPak. Using this software, regressions were produced. In a regression analysis correlation, when an 
intercept p-value is less than .01, this shows that the data is statistically significant. If the data is 
statistically significant, the line of best fit uses the empirical data points to give a forecast of future data.  
In the plots below, the blue data points represent the empirical data points, while the red points 
represent the forecast of future data. An example of the intercept p-value and other regression statistics 
can be seen below in. 
 
Table 3:  Regression Statistics for Age &Menopausal Stage Correlation 
 
  Coefficients 
Standard 
Error 
t Stat P-value 
Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 40.72444 2.382142 17.09572 1.45E-18 35.88843 45.56045 35.88843 45.56045 
Menopausal 
Stage 
3.619701 1.027169 3.523957 0.001206 1.534436 5.704965 1.534436 5.704965 
 
 Below is a correlation plot made between the menopausal stage of the subjects in the study and their 
reported age. 
 
Figure 12: Scatter Plot of Reported Age and Menopausal Stage 
 
In Figure 12 it can be seen that peri-menopausal and the post-menopauasl subjects are in their mid-
fifties to sixties as literature states. Likewise, the menstruating to pre-menopausal subjects are in their 
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Shown is the reported age of the subjects participating in the study (y-
axis) correlated with the subjects’ menopausal stage (x-axis). The 
numbers 0, 1, 2, and 3 are ordinal values that indicate that the subject 
is pre-menopausal, menopausal, peri-menopausal and post-
menopausal respectively. 
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mid-fifties or below. There was an intercept p-value of 1.45E-18 suggesting that the correlation between the 
subjects reported age and menopausal stage is statistically significant. 
 
Figure 13: Scatter Plot of YMRS Total Score and Menopausal Stage 
 
Figure 13 shows the correlation plot for the subjects’ YMRS total scores and their menopausal stages. 
The empirical data consists of a data plot for each visit and subsequent YMRS evaluation. It is apparent 
from the data that the peri-menopausal and post-menopausal subjects display the highest YMRS scores 
meaning that they experience more intense manic episodes. An intercept p-value was inconclusive as to 
the correlation between the YMRS score and the subjects’ menopausal stage. As such no statistical 
correlation between menopausal stage and manic episodes was found. However, visually the graphical 
data suggests that bipolar symptoms may increase during menopausal transitioning, giving rise to a high 
YMRS score. 
 
Figure 14: Scatter Plot of MADRS Total Score and Menopausal Sage 
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Figure 14 shows the correlation plot for the subjects’ MADRS total scores and their menopausal stage. 
The empirical data consists of a data plot for each visit and subsequent MADRS evaluation. It is apparent 
from the data that the peri-menopause and post-menopause subjects display the highest MADRS scores 
meaning that they experience more intense depressive episodes. An intercept p-value was inconclusive 
as to the correlation between the MADRS score and the subjects’ menopausal stage. As such no 
statistical correlation between menopausal stage and depressive episodes was found. 
 
Correlation between FSH Levels to Bipolarity Index Score 
 
Figure 15: Scatter Plot of Bipolarity Index and FSH Levels 
 
Figure 15 shows the correlation plot for the subjects’ bipolarity index total scores and follicular 
stimulating hormone (FSH) levels. The empirical data consists of a bipolarity index value and subsequent 
FSH level per visit. The bipolarity index score is comprised of five scored categories, on a spectrum that 
add together, from which a subtype diagnosis is made. The categories from which the score is derived, 
include, the subjects’ family history, response to medicinal treatment, course of illness, age of onset of 
first mood episode and mania symptomology. It can be seen that the empirical data fits the line of best 
fit somewhat. However, an intercept p-value was inconclusive as to the correlation between the 
bipolarity index score and the subjects’ FSH levels. As such no statistical correlation between 
menopausal stage and depressive episodes was found. 
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Conclusion  
The data from the “Demographics Form” was visually displayed as bar graphs representing the 
makeup of the subjects in the study. On preliminary demographic examination we found that the 
majority of the subjects were white, non-Hispanic individuals who were married and had some college 
background. Most received a household income of $20,000-$29,999 and held either a professional or 
clerical occupation. In the future, variables in the “Demographics Form”, such as, household income and 
marital status, can be correlated with bipolar disorder symptoms in order to see if demographics have 
an effect on symptom severity.  
As shown in the correlations section of the data analysis, no strong statistical correlations were 
found using a regression analysis.  However, background research suggested a correlation may exist 
between menopause and bipolar disorder due to severe hormonal fluctuations in endocrine levels. 
Literature suggests that the menopausal transition may be associated with greater mood flux for those 
diagnosed with bipolar disorder (Kukopulos, Reginaldi, Laddomada, & Floris, 1980).  Despite these 
correlations, regression analysis failed to validate all literature-based relationships. For instance, it is 
known that there is a correlation between a woman’s age and her menopausal stage. This relationship 
was confirmed. However, when making correlations between the MADRS total scores, YMRS total scores 
and the subjects’ menopausal stage, the data failed to lend itself to the establishment of a statistically 
significant correlation as indicated by the p-value. . Nevertheless biological correlations have been 
underlined in previous studies on the basis that elevated endocrine levels during menstrual transitions 
alter the mood severity of both manic and depressive episodes, thus exacerbating a subjects’ bipolar 
disorder at its foundation (Steiner, Dunn, & Born, 2001). Furthermore, some research points to similar 
mood and in turn symptom elevation as a result of postpartum states (Payne, 2007). 
Despite the statistical inconclusiveness, the empirical data as seen in Figures 15 and 16 shows 
that peri-menopausal and post-menopausal subjects may in fact have a tendency to experience more 
intense manic and depressive episodes. There may be a relationship between the line of best fit and the 
empirical data in Figure 17. The failure to come up with statistically significant intercept p-values from 
the regressions in Figures 15-17, may be due to the current small sample size of the study. There are 
currently only 39 participants in the study, while the goal for participants is set at approximately 70 
subjects. Despite the current sample size, a better way to analyze the data of this study is to use a 
repeated measures design. This design model lends itself well to longitudinal studies in which the same 
subjects are evaluated for different measures over a period of time (Toutenburg, 2009). This type of 
model will allow for stronger correlations to be made with smaller sample sizes. At this time in the study 
however, there is simply not enough data per menstrual phase to draw conclusions. 
The other possible issue with making statistical correlations between numerical representations 
of symptom severity is that, to date, individuals are diagnosed on a continuum divided by Bipolar I, 
Bipolar II, and Bipolar NOS. With the specific symptoms of the disorder falling into such broad 
categories, especially the heterogeneous NOS classification, it may be difficult to make conclusive 
correlations between subjects’ menopausal stage and bipolar symptoms.  
This MQP endeavored to consider alternative options that may be associated with mood 
stability in bipolar disorder. To accomplish this, researchers drafted a questionnaire, which would result 
in a matrix of prescription treatments coupled with hypothesized dietary supplements associated with 
30 | P a g e  
 
mood stability. These dietary supplements included omega-3 fatty acids and vitamins, such as vitamin B 
complex. Said supplements were chosen because they have been associated clinically with mood 
stability.  Vitamins, like B6, are known to contribute to serotonin precursor development, which could 
aid a treatment such as an SSRI to combat depressive symptoms more effectively, for instance  
(Bernstein, 2006). 
Due to time constraints and pending IRB approvals, this questionnaire was finalized, but data 
collection from study participants never came to fruition. Even further research in other subsequent 
studies could lead to the development of animal models to examine bipolar disorder. For instance, there 
already exists a mouse model for depression. The effectiveness of antidepressants has been tested on 
this model, which houses genes associated with depression-syndrome (Urani, Chourbaji, & Gass, 2005). 
However if a model displaying both manic and depressive symptoms was developed, the study of 
bipolar disorder could take great strides. 
Herein we learned the criteria for bipolar disorders and menopausal staging and its application 
in clinical research.  We gained experience in the execution of clinical research in an outpatient setting 
on an observational study examining the clinical course of bipolar disorder during the menaopausal 
transition. In particular, we mastered REDCap software for data entry and learned basic analytical 
techniques.  On preliminary analysis, while age was associated with menopausal stage, neither severity 
of mood elevations nor depression was associated with menopausal stage of FSH levels.  While our 
initial report does not reveal significant associations and it may be that menopausal stage and hormonal 
levels are not associated with mood, further more thorough analysis with a larger study sample will be 
performed by the primary investigator.   
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Study Improvements 
 After completing data entry into the REDCap database, a series of recommendations were made 
regarding computer-based data and paper-form data. The following list consists of possible 
improvements that can be made to facilitate the data entry process, as well as maintaining consistency.  
Data Collection – Databases and Forms 
General 
• The text fields are inconsistent in accepting the entry for blank vs. 0. During certain cases, if age 
is left blank, sometimes the database allows one to enter blank and sometimes it requires the 
age 0 as a numerical digit. 
PHI 
• Under Preferred Contact Number there is an option for other but it does not correspond to an 
optional field in the database. 
Menstrual History 
• If the time period of last period is less than 1 month (i.e. 4 days) the equation will return -1 
months. 
• In page 2, in the past month, have you had hot flashes that awakened you at night or caused 
night sweats? is indented, so it appears to be part of the In the past month, have you had hot 
flashes that occur during the day? section. If the patient answers no to the latter, then they 
assume to skip the aforementioned question.  
• Under would you describe yourself as currently… it may be assumed that a portion of the 
question was your menopause… only pertains to post-menopausal.  
• Under the amount of time that the subject exercised, on REDCap it asks for the exercise 
duration in minutes; however, on the actual form there is no specification and therefore the 
subject just gives a general period of time. (i.e. every day, twice a week, etc.). 
CMF 
• If Yes is not marked for Alcohol Abuse, the number of drinks that the subject has per week 
cannot be entered. If the value is like 4 drinks per week, that is not necessarily abuse. 
• When the subject is not currently abusing alcohol, but has in the past (i.e. subject #313) there is 
no way to indicate that they have and that they are sober for x-period of time. 
• On the CMF paper form, under Onset of Menses it gives the option for early, late and 
unavailable if the subject is still menstruating; however, these options do not appear on the 
database form.  
The Greene Climacteric Scale 
• The word “Climacteric” in the title of the Greene Climacteric Scale form is misspelled.  
MADRS 
• While the physician is checking off the boxes based upon subject’s response, there is no actual 
place on the REDCap database to add the physician’s comments that are written (i.e. answers to 
the guided questions). 
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ADE1-5 
• In REDCap, it asks for a +/- value for Alcohol Abuse and does not give a place to enter the 
number of drinks written on the physical sheet. So if the subject has 2 drinks per day as shown 
on the sheet, that is not necessarily alcohol abuse. 
• Under Past Depression the program asks to rate (no, probable or definite) and then a field 
appears for comments even though there is no actual field on the actual form. 
• Under If either of above answers is "definite," answer the following questions. If not, skip to 
next section under SI the actual form has LNWL, Active and Passive as choices but REDCap has 
those 3 in addition to refused, don’t know and blank. 
• Under Perimenstrual exacerbation on REDCap there is a comment section even though there is 
none on the actual form. 
• Under Past psychiatric history on the actual form there is a Comments Section that does not 
appear in REDCap. 
• Under Other current symptoms the physician is able to choose between: euthymic, depressed, 
elevated, mixed and fill in, however you can only choose one on the online form even though 
multiple may be selected on the actual form. 
•  Under Have you ever had a time...when you were feeling so good or hyper that other PEOPLE 
THOUGHT YOU WERE NOT YOUR NORMAL SELF? the fields for the date should only appear if 
the user selects yes as a response. This should not happen when they select probable as a 
response. 
• It is often forgotten to circle yes or no under abuse or trauma on the Past Psychiatric History 
form. 
• On page 3 for Number of Phases, the field for past 12 months should have a 0 as an option. 
ADE6-8 
• In the Treatment History section, there should be a blank option as opposed to don’t know or 
didn’t ask. 
• Under Psychoactive Substance Use History from Nicotine on, for those substances if the current 
use is marked as yes the additional fields for the age last use, age peak use, age onset and 
abuse treatment do not generate. 
• Under Psychoactive Substance Use History: All fields appear for EtOH only, while the rest 
concentrate only on current use and history of abuse. 
• Under Neuro-endocrine what is the purpose of having Other entry in review of systems? 
Followed by Indicate yes, no, didn't ask? Is there a difference between the two? 
ADE9 
• Under Family History if the user checks yes in the dropdown field, then there is no 
corresponding checkbox for nieces, and nephews. This is a common write-in on the actual form. 
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Appendix  
Appendix A: Table of Subject Visits and Menstrual Status  
Subject Identifier Visits Completed Status Menopausal Stage 
304 5 Complete Post-menopausal  
305 5 Complete Post-menopausal 
306 5 Complete Post-menopausal 
307 4 Dropped Peri-menopausal 
308 4 Still Participating Peri-menopausal 
309 5 Complete Post-menopausal 
310 5 Complete Post-menopausal 
311 5 Complete Peri-menopausal 
312 2 Lost to Follow-up Peri-menopausal 
313 5 Complete Post-menopausal 
314 5 Complete Post-menopausal 
315 5 Complete Peri-menopausal 
316 5 Complete Peri-menopausal 
317 1 Lost to Follow-up Peri-menopausal 
318 5 Complete Post-menopausal 
319 5 Complete Post-menopausal 
320 3 Lost to Follow-up Menstruating 
321 5 Complete Menstruating  
322 5 Complete Menstruating  
323 5 Complete Peri-menopausal 
324 1 Lost to Follow-up Peri-menopausal 
325 5 Complete Post-menopausal 
326 1 Lost to Follow-up Peri-menopausal 
327 2 Lost to Follow-up Peri-menopausal 
328 5 Complete Peri-menopausal 
329 1 Lost to Follow-up Peri-menopausal 
330 1 Lost to Follow-up Peri-menopausal 
331 5 Complete Pre-menopausal  
332 3 Still Participating Post-menopausal 
333 1 Lost to Follow-up Peri-menopausal 
334 4 Still Participating Peri-menopausal 
335 4 Still Participating Peri-menopausal (late) 
336 2 Still Participating Post-menopausal 
337 3 Still Participating Peri-menopausal (late)  
338 1 Lost to Follow-up Peri-menopausal  
339 2 Still Participating Peri-menopausal (early)  
340 1 Still Participating Peri-menopausal  
341 1 Still Participating Post-menopausal 
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Appendix B: Affective Disorders Evaluation (ADE) Form 
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Appendix C: Demographics Form
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Appendix D: Greene Climacteric Scale 
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Appendix E: FSH and Estradiol Blood Panel 
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Appendix F: Menstrual History Form 
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Appendix G: Medical History Form  
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Appendix H: Young Mania Rating Scale 
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Appendix I: Montgomery-Aspberg Depression Rating Scale (MADRS)  
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Appendix J: Correlations  
Correlation between Menopausal Stage and Age 
 
Regression Statistics 
Multiple R 0.434473 
R Square 0.188767 
Adjusted R 
Square 0.164907 
Standard Error 2.852284 
Observations 36 
 
  df SS MS F 
Significance 
F 
Regression 1 64.36435 64.36435 7.911517 0.008102 
Residual 34 276.6079 8.135526   
Total 35 340.9722       
 
  Coefficients 
Standard 
Error 
t Stat P-value 
Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 40.72444 2.382142 17.09572 1.45E-18 35.88843 45.56045 35.88843 45.56045 
Menopausal 
Stage 
3.619701 1.027169 3.523957 0.001206 1.534436 5.704965 1.534436 5.704965 
 
 
Observation 
Predicted Age of 
onset (1st affective 
episode/syndrome) 
Residuals 
Standard 
Residuals 
1 16.51717 -6.51717 -2.31825 
2 15.75307 -5.75307 -2.04645 
3 14.98898 -4.98898 -1.77465 
4 16.51717 -1.51717 -0.53968 
5 15.37102 -0.37102 -0.13198 
6 15.75307 -0.75307 -0.26788 
7 17.28126 -2.28126 -0.81148 
-10
0
10
20
0 1 2 3 4
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s 
Menopausal Stage 
Menopausal Stage Residual 
Plot 
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8 14.22488 0.775118 0.275721 
9 18.04535 -3.04535 -1.08328 
10 16.89921 -1.89921 -0.67558 
11 16.89921 -1.89921 -0.67558 
12 13.07874 1.92126 0.68342 
13 16.51717 -1.51717 -0.53968 
14 17.28126 -2.28126 -0.81148 
15 17.28126 -2.28126 -0.81148 
16 17.28126 -2.28126 -0.81148 
17 14.60693 0.393071 0.139821 
18 15.75307 -0.75307 -0.26788 
19 16.89921 -1.89921 -0.67558 
20 14.22488 0.775118 0.275721 
21 15.37102 -0.37102 -0.13198 
22 16.51717 -1.51717 -0.53968 
23 16.51717 3.482835 1.238895 
24 18.04535 1.954646 0.695296 
25 18.4274 1.572598 0.559396 
26 17.28126 2.71874 0.967096 
27 18.04535 1.954646 0.695296 
28 15.37102 4.628976 1.646595 
29 18.04535 1.954646 0.695296 
30 16.13512 3.864882 1.374795 
31 14.60693 5.393071 1.918394 
32 18.04535 1.954646 0.695296 
33 17.28126 2.71874 0.967096 
34 18.04535 1.954646 0.695296 
35 17.66331 2.336693 0.831196 
36 18.4274 1.572598 0.559396 
 
Correlation of Menopausal Stage to YMRS Sum 
 
Regression Statistics 
Multiple R 0.756118 
R Square 0.571715 
Adjusted R 
Square 0.564362 
Standard Error 1.577287 
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5
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Residual Plot 
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Observations 137 
 
  df SS MS F 
Significance 
F 
Regression 1 451.6546 451.6546 181.5453 9.39E-27 
Residual 136 338.3454 2.487834   
Total 137 790       
 
  Coefficients Standard 
Error 
t Stat P-value Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 0 #N/A #N/A #N/A #N/A #N/A #N/A #N/A 
YMRS 
Score 
0.191298 0.014198 13.47388 8.15E-27 0.163221 0.219375 0.163221 0.219375 
 
 
Observation 
Predicted 
Menopausal 
Stage 
Residuals 
Standard 
Residuals 
1 0 3 1.90898 
2 0 3 1.90898 
3 0 3 1.90898 
4 0 3 1.90898 
5 0 0 0 
6 0 0 0 
7 0 1 0.636327 
8 0 1 0.636327 
9 0 1 0.636327 
10 0 3 1.90898 
11 0 2 1.272653 
12 0 2 1.272653 
13 0 2 1.272653 
14 0 2 1.272653 
15 0.191298 2.808702 1.787252 
16 0.191298 2.808702 1.787252 
17 0.191298 2.808702 1.787252 
18 0.191298 1.808702 1.150925 
19 0.191298 2.808702 1.787252 
20 0.191298 -0.1913 -0.12173 
21 0.191298 -0.1913 -0.12173 
22 0.191298 2.808702 1.787252 
23 0.191298 2.808702 1.787252 
24 0.191298 2.808702 1.787252 
25 0.191298 1.808702 1.150925 
26 0.382596 2.617404 1.665524 
27 0.382596 2.617404 1.665524 
28 0.382596 2.617404 1.665524 
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29 0.382596 2.617404 1.665524 
30 0.382596 1.617404 1.029197 
31 0.382596 -0.3826 -0.24346 
32 0.382596 -0.3826 -0.24346 
33 0.382596 1.617404 1.029197 
34 0.382596 1.617404 1.029197 
35 0.382596 1.617404 1.029197 
36 0.382596 0.617404 0.392871 
37 0.382596 0.617404 0.392871 
38 0.573894 2.426106 1.543796 
39 0.573894 2.426106 1.543796 
40 0.573894 2.426106 1.543796 
41 0.573894 1.426106 0.907469 
42 0.573894 1.426106 0.907469 
43 0.573894 2.426106 1.543796 
44 0.573894 2.426106 1.543796 
45 0.765192 2.234808 1.422068 
46 0.765192 2.234808 1.422068 
47 0.765192 2.234808 1.422068 
48 0.765192 2.234808 1.422068 
49 0.765192 -0.76519 -0.48691 
50 0.765192 2.234808 1.422068 
51 0.95649 1.04351 0.664013 
52 0.95649 2.04351 1.30034 
53 0.95649 -0.95649 -0.60864 
54 0.95649 1.04351 0.664013 
55 0.95649 1.04351 0.664013 
56 0.95649 1.04351 0.664013 
57 1.147788 0.852212 0.542285 
58 1.147788 1.852212 1.178612 
59 1.147788 1.852212 1.178612 
60 1.147788 0.852212 0.542285 
61 1.147788 1.852212 1.178612 
62 1.147788 0.852212 0.542285 
63 1.147788 0.852212 0.542285 
64 1.147788 1.852212 1.178612 
65 1.147788 1.852212 1.178612 
66 1.147788 -1.14779 -0.73037 
67 1.147788 -1.14779 -0.73037 
68 1.147788 1.852212 1.178612 
69 1.147788 0.852212 0.542285 
70 1.147788 1.852212 1.178612 
71 1.147788 0.852212 0.542285 
72 1.339086 1.660914 1.056884 
73 1.339086 1.660914 1.056884 
74 1.339086 0.660914 0.420557 
75 1.339086 1.660914 1.056884 
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76 1.339086 0.660914 0.420557 
77 1.339086 1.660914 1.056884 
78 1.339086 0.660914 0.420557 
79 1.339086 0.660914 0.420557 
80 1.339086 0.660914 0.420557 
81 1.339086 0.660914 0.420557 
82 1.339086 1.660914 1.056884 
83 1.530384 1.469616 0.935156 
84 1.530384 0.469616 0.298829 
85 1.530384 0.469616 0.298829 
86 1.530384 0.469616 0.298829 
87 1.530384 1.469616 0.935156 
88 1.530384 0.469616 0.298829 
89 1.530384 0.469616 0.298829 
90 1.721682 0.278318 0.177101 
91 1.721682 1.278318 0.813428 
92 1.721682 0.278318 0.177101 
93 1.721682 0.278318 0.177101 
94 1.91298 1.08702 0.6917 
95 1.91298 1.08702 0.6917 
96 1.91298 0.08702 0.055373 
97 1.91298 1.08702 0.6917 
98 1.91298 -1.91298 -1.21728 
99 1.91298 0.08702 0.055373 
100 1.91298 0.08702 0.055373 
101 2.104278 0.895722 0.569972 
102 2.104278 0.895722 0.569972 
103 2.104278 -0.10428 -0.06635 
104 2.104278 -0.10428 -0.06635 
105 2.104278 -0.10428 -0.06635 
106 2.295576 0.704424 0.448244 
107 2.295576 -0.29558 -0.18808 
108 2.295576 -0.29558 -0.18808 
109 2.295576 0.704424 0.448244 
110 2.295576 -2.29558 -1.46074 
111 2.295576 -0.29558 -0.18808 
112 2.295576 -0.29558 -0.18808 
113 2.486874 0.513126 0.326516 
114 2.486874 -0.48687 -0.30981 
115 2.486874 -0.48687 -0.30981 
116 2.678172 -0.67817 -0.43154 
117 2.678172 0.321828 0.204788 
118 2.86947 0.13053 0.08306 
119 2.86947 -0.86947 -0.55327 
120 2.86947 0.13053 0.08306 
121 3.060768 -0.06077 -0.03867 
122 3.060768 -0.06077 -0.03867 
65 | P a g e  
 
123 3.060768 -1.06077 -0.675 
124 3.060768 -1.06077 -0.675 
125 3.252066 -0.25207 -0.1604 
126 3.252066 -1.25207 -0.79672 
127 3.252066 -1.25207 -0.79672 
128 3.443364 -1.44336 -0.91845 
129 3.443364 -1.44336 -0.91845 
130 3.634662 -0.63466 -0.40385 
131 3.634662 -0.63466 -0.40385 
132 3.82596 -0.82596 -0.52558 
133 4.017258 -1.01726 -0.64731 
134 4.017258 -1.01726 -0.64731 
135 4.017258 -2.01726 -1.28364 
136 4.591152 -2.59115 -1.64882 
137 4.973748 -2.97375 -1.89228 
 
Correlation of Menopausal Stage to MADRS Sum – Residual Output 
 
Regression Statistics 
Multiple R 0.792878 
R Square 0.628656 
Adjusted R 
Square 0.621303 
Standard Error 10.14359 
Observations 137 
 
  df SS MS F 
Significance 
F 
Regression 1 23689.63 23689.63 230.237 5.73E-31 
Residual 136 13993.37 102.8924   
Total 137 37683       
 
Coefficients 
Standard 
Error t Stat P-value Lower 95% Upper 95% 
Lower 
95.0% 
Upper 
95.0% 
0 #N/A #N/A #N/A #N/A #N/A #N/A #N/A 
-20
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5.46221662
5 
0.35998250
9 
15.173561
2 
4.76589E
-31 
4.75032933
6 
6.17410391
4 
4.75032933
6 
6.17410391
4 
 
Observation 
Predicted 
MADRS 
Score 
Residuals 
Standard 
Residuals 
1 16.38665 -16.3866 -1.6214 
2 16.38665 -16.3866 -1.6214 
3 5.462217 -5.46222 -0.54047 
4 5.462217 -5.46222 -0.54047 
5 5.462217 -5.46222 -0.54047 
6 16.38665 -16.3866 -1.6214 
7 10.92443 -10.9244 -1.08093 
8 0 1 0.098946 
9 16.38665 -15.3866 -1.52245 
10 10.92443 -9.92443 -0.98199 
11 16.38665 -14.3866 -1.4235 
12 16.38665 -14.3866 -1.4235 
13 16.38665 -14.3866 -1.4235 
14 10.92443 -8.92443 -0.88304 
15 16.38665 -14.3866 -1.4235 
16 10.92443 -8.92443 -0.88304 
17 0 2 0.197892 
18 5.462217 -3.46222 -0.34257 
19 10.92443 -8.92443 -0.88304 
20 10.92443 -8.92443 -0.88304 
21 10.92443 -8.92443 -0.88304 
22 16.38665 -13.3866 -1.32456 
23 10.92443 -7.92443 -0.78409 
24 0 3 0.296839 
25 16.38665 -12.3866 -1.22561 
26 10.92443 -6.92443 -0.68515 
27 10.92443 -6.92443 -0.68515 
28 0 4 0.395785 
29 5.462217 -1.46222 -0.14468 
30 10.92443 -5.92443 -0.5862 
31 16.38665 -11.3866 -1.12667 
32 16.38665 -11.3866 -1.12667 
33 16.38665 -11.3866 -1.12667 
34 16.38665 -11.3866 -1.12667 
35 16.38665 -10.3866 -1.02772 
36 10.92443 -4.92443 -0.48725 
37 10.92443 -4.92443 -0.48725 
38 10.92443 -4.92443 -0.48725 
39 16.38665 -9.38665 -0.92877 
40 10.92443 -3.92443 -0.38831 
41 16.38665 -9.38665 -0.92877 
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42 10.92443 -3.92443 -0.38831 
43 16.38665 -8.38665 -0.82983 
44 16.38665 -8.38665 -0.82983 
45 16.38665 -8.38665 -0.82983 
46 16.38665 -8.38665 -0.82983 
47 10.92443 -2.92443 -0.28936 
48 10.92443 -2.92443 -0.28936 
49 10.92443 -2.92443 -0.28936 
50 16.38665 -7.38665 -0.73088 
51 16.38665 -7.38665 -0.73088 
52 16.38665 -7.38665 -0.73088 
53 16.38665 -7.38665 -0.73088 
54 10.92443 -1.92443 -0.19042 
55 10.92443 -0.92443 -0.09147 
56 10.92443 -0.92443 -0.09147 
57 16.38665 -5.38665 -0.53299 
58 10.92443 0.075567 0.007477 
59 0 11 1.088408 
60 0 11 1.088408 
61 10.92443 0.075567 0.007477 
62 10.92443 0.075567 0.007477 
63 10.92443 0.075567 0.007477 
64 16.38665 -4.38665 -0.43404 
65 16.38665 -4.38665 -0.43404 
66 16.38665 -4.38665 -0.43404 
67 10.92443 1.075567 0.106423 
68 16.38665 -4.38665 -0.43404 
69 0 12 1.187355 
70 0 12 1.187355 
71 10.92443 1.075567 0.106423 
72 16.38665 -3.38665 -0.3351 
73 16.38665 -3.38665 -0.3351 
74 10.92443 2.075567 0.205369 
75 10.92443 2.075567 0.205369 
76 10.92443 2.075567 0.205369 
77 16.38665 -2.38665 -0.23615 
78 16.38665 -2.38665 -0.23615 
79 16.38665 -2.38665 -0.23615 
80 10.92443 3.075567 0.304316 
81 10.92443 3.075567 0.304316 
82 0 14 1.385247 
83 16.38665 -1.38665 -0.1372 
84 10.92443 4.075567 0.403262 
85 10.92443 4.075567 0.403262 
86 10.92443 4.075567 0.403262 
87 10.92443 4.075567 0.403262 
88 0 16 1.583139 
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89 10.92443 5.075567 0.502208 
90 16.38665 0.61335 0.060689 
91 16.38665 0.61335 0.060689 
92 16.38665 0.61335 0.060689 
93 0 17 1.682086 
94 10.92443 6.075567 0.601154 
95 16.38665 0.61335 0.060689 
96 16.38665 1.61335 0.159635 
97 10.92443 7.075567 0.700101 
98 16.38665 1.61335 0.159635 
99 10.92443 7.075567 0.700101 
100 16.38665 1.61335 0.159635 
101 16.38665 2.61335 0.258581 
102 16.38665 3.61335 0.357527 
103 16.38665 3.61335 0.357527 
104 16.38665 4.61335 0.456474 
105 10.92443 10.07557 0.996939 
106 16.38665 4.61335 0.456474 
107 16.38665 4.61335 0.456474 
108 10.92443 10.07557 0.996939 
109 16.38665 5.61335 0.55542 
110 10.92443 11.07557 1.095885 
111 10.92443 11.07557 1.095885 
112 10.92443 12.07557 1.194832 
113 10.92443 12.07557 1.194832 
114 10.92443 12.07557 1.194832 
115 10.92443 13.07557 1.293778 
116 16.38665 7.61335 0.753312 
117 16.38665 7.61335 0.753312 
118 16.38665 8.61335 0.852258 
119 10.92443 14.07557 1.392724 
120 10.92443 14.07557 1.392724 
121 16.38665 8.61335 0.852258 
122 16.38665 9.61335 0.951205 
123 10.92443 16.07557 1.590616 
124 16.38665 11.61335 1.149097 
125 10.92443 19.07557 1.887455 
126 16.38665 13.61335 1.346989 
127 16.38665 14.61335 1.445936 
128 16.38665 14.61335 1.445936 
129 10.92443 21.07557 2.085348 
130 10.92443 21.07557 2.085348 
131 16.38665 15.61335 1.544882 
132 10.92443 22.07557 2.184294 
133 10.92443 22.07557 2.184294 
134 10.92443 23.07557 2.28324 
135 10.92443 24.07557 2.382186 
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136 16.38665 18.61335 1.841721 
137 10.92443 29.07557 2.876917 
 
Correlation between FSH and Bipolar Total Score 
 
 
Regression Statistics 
Multiple R 0.736215 
R Square 0.542013 
Adjusted R 
Square 0.531374 
Standard Error 54.59239 
Observations 95 
 
  df SS MS F Significance F 
Regression 1 331549 331549.0472 111.2458 1.44E-17 
Residual 94 280151 2980.329285   
Total 95 611700       
 
 
  Coefficients Standard Error t Stat P-value 
Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 0 #N/A #N/A #N/A #N/A #N/A #N/A #N/A 
FSH  0.852761 0.080851 10.54731137 1.27E-17 0.692229 1.013293 0.692229 1.013293 
 
Observation 
Predicted 
BP Total 
score 
Residuals Standard Residuals 
1 34.36627 40.63373 0.748259789 
2 72.8258 2.1742 0.040037346 
3 72.8258 2.1742 0.040037346 
4 69.75586 5.24414 0.096569514 
5 82.97366 -22.9737 -0.423054079 
6 40.84726 19.15274 0.352692898 
7 49.6307 10.3693 0.190948083 
8 49.80125 10.19875 0.187807407 
9 41.35891 18.64109 0.34327087 
10 56.96444 18.03556 0.332120216 
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11 126.5498 -61.5498 -1.133423069 
12 119.3013 -54.3013 -0.999944338 
13 113.9289 -48.9289 -0.901013043 
14 137.5504 -72.5504 -1.335996672 
15 77.43071 7.56929 0.139386561 
16 77.00433 7.995671 0.147238251 
17 84.42335 0.576649 0.010618844 
18 11.85338 83.14662 1.531123959 
19 4.60491 90.39509 1.664602689 
20 8.78344 86.21656 1.587656127 
21 8.612887 86.38711 1.590796803 
22 5.372395 89.6276 1.650469647 
23 9.636201 35.3638 0.651215409 
24 11.25645 33.74355 0.621378987 
25 90.90434 9.095664 0.167494356 
26 82.29145 17.70855 0.326098495 
27 84.5939 15.4061 0.283699369 
28 67.70923 27.29077 0.502552562 
29 61.22825 33.77175 0.62189825 
30 55.08837 39.91163 0.734962587 
31 29.59081 55.40919 1.020346185 
32 87.74912 -2.74912 -0.050624339 
33 67.96506 17.03494 0.31369408 
34 74.44605 10.55395 0.194348391 
35 74.6166 10.3834 0.191207715 
36 29.33498 65.66502 1.209204666 
37 31.29633 63.70367 1.173086892 
38 33.85462 61.14538 1.125976752 
39 26.09449 68.90551 1.268877511 
40 2.473007 72.52699 1.335566205 
41 92.18348 -12.1835 -0.224355649 
42 89.19881 -9.19881 -0.169393819 
43 87.15219 -7.15219 -0.131705706 
44 25.24173 54.75827 1.008359689 
45 27.80001 52.19999 0.961249549 
46 12.10921 67.89079 1.250191743 
47 4.946015 25.05399 0.461362798 
48 8.612887 21.38711 0.393838264 
49 5.457671 69.54233 1.280604374 
50 5.884052 69.11595 1.272752684 
51 6.054604 68.9454 1.269612008 
52 5.201843 69.79816 1.285315388 
53 6.736813 68.26319 1.257049304 
54 9.039268 75.96073 1.398797645 
55 5.287119 79.71288 1.467892518 
56 5.884052 79.11595 1.456900152 
57 6.736813 78.26319 1.441196772 
58 6.395708 78.60429 1.447478124 
59 3.325768 81.67423 1.504010292 
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60 4.860738 80.13926 1.475744208 
61 7.077917 77.92208 1.43491542 
62 7.077917 77.92208 1.43491542 
63 7.24847 52.75153 0.971406075 
64 131.1547 -46.1547 -0.849926386 
65 110.7737 -25.7737 -0.474615601 
66 137.8062 -52.8062 -0.972412751 
67 6.395708 88.60429 1.631625591 
68 5.628223 44.37178 0.817095029 
69 6.907365 43.09263 0.793539959 
70 7.589574 57.41043 1.057198456 
71 26.7767 38.2233 0.703872404 
72 8.186507 61.81349 1.138279824 
73 32.91658 62.08342 1.14325047 
74 15.3497 79.6503 1.4667401 
75 7.589574 87.41043 1.609640859 
76 3.837425 91.16257 1.678735732 
77 33.08713 61.91287 1.140109794 
78 70.26752 -5.26752 -0.096999982 
79 1.32178 63.67822 1.1726183 
80 22.17179 32.82821 0.604523189 
81 32.66075 52.33925 0.963814016 
82 35.13376 49.86624 0.918274214 
83 16.28774 68.71226 1.265318914 
84 116.9135 -36.9135 -0.679753672 
85 81.95034 -1.95034 -0.035915088 
86 102.6724 -22.6724 -0.417507224 
87 61.56935 -16.5694 -0.30512044 
88 51.67732 -6.67732 -0.12296123 
89 113.5025 -18.5025 -0.34071895 
90 104.0369 -9.03686 -0.166411431 
91 5.884052 84.11595 1.548973885 
92 5.201843 94.79816 1.745684057 
93 27.03253 72.96747 1.343677526 
94 8.186507 51.81349 0.954132356 
95 70.60862 4.391379 0.080866134 
 
